Literature DB >> 17157786

PU.1 and Junb: suppressing the formation of acute myeloid leukemia stem cells.

Tim C P Somervaille1, Michael L Cleary.   

Abstract

Improved understanding of the molecular pathways that suppress the genesis and maintenance of cancer stem cells will facilitate development of rationally targeted therapies. PU.1 is a transcription factor that is required for normal myelomonocytic differentiation in hematopoiesis, and reduced PU.1 activity has been associated with myeloid leukemogenesis in man and in mouse models. A recent study by Steidl et al. demonstrates that Junb and Jun, two AP-1 transcription factors, are critical downstream effectors of the tumor suppressor activity of PU.1, and that reduced expression of Junb, in particular, may be a common feature of acute myeloid leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157786     DOI: 10.1016/j.ccr.2006.11.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  12 in total

Review 1.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

2.  IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.

Authors:  Sun-Mi Park; Hyunwoo Cho; Angela M Thornton; Trevor S Barlowe; Timothy Chou; Sagar Chhangawala; Lauren Fairchild; James Taggart; Arthur Chow; Alexandria Schurer; Antoine Gruet; Matthew D Witkin; Jun Hyun Kim; Ethan M Shevach; Andrei Krivtsov; Scott A Armstrong; Christina Leslie; Michael G Kharas
Journal:  Cell Stem Cell       Date:  2018-11-21       Impact factor: 24.633

3.  Common and distinct mechanisms of different redox-active carcinogens involved in the transformation of mouse JB6P+ cells.

Authors:  Sun Yang; Bobbye Misner; Rita Chiu; Frank L Meyskens
Journal:  Mol Carcinog       Date:  2008-07       Impact factor: 4.784

4.  Cell cycle control in acute myeloid leukemia.

Authors:  Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

5.  Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.

Authors:  Kyle A Romine; Tamilla Nechiporuk; Daniel Bottomly; Sophia Jeng; Shannon K McWeeney; Andy Kaempf; M Ryan Corces; Ravindra Majeti; Jeffrey W Tyner
Journal:  Blood Cancer Discov       Date:  2021-07-01

6.  The transcription factor PU.1 regulates γδ T cell homeostasis.

Authors:  Rukhsana Jabeen; Hua-Chen Chang; Ritobrata Goswami; Stephen L Nutt; Mark H Kaplan
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

7.  The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.

Authors:  Wen-Tao Wang; Tian-Qi Chen; Zhan-Cheng Zeng; Qi Pan; Wei Huang; Cai Han; Ke Fang; Lin-Yu Sun; Qian-Qian Yang; Dan Wang; Xue-Qun Luo; Yu-Meng Sun; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2020-06-17       Impact factor: 17.388

8.  JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML.

Authors:  Shan-He Yu; Kang-Yong Zhu; Juan Chen; Xiang-Zhen Liu; Peng-Fei Xu; Wu Zhang; Li Yan; He-Zhou Guo; Jiang Zhu
Journal:  Nat Commun       Date:  2018-08-22       Impact factor: 14.919

9.  The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia.

Authors:  Yaser Heshmati; Gözde Türköz; Aditya Harisankar; Shabnam Kharazi; Johan Boström; Esmat Kamali Dolatabadi; Aleksandra Krstic; David Chang; Robert Månsson; Mikael Altun; Hong Qian; Julian Walfridsson
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

Review 10.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.